BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30873825)

  • 1. Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study.
    Kimyon Cömert G; Türkmen O; Boyraz G; Yalçın İ; Altın D; Karalök A; Şahin H; Taşkın S; Başaran D; Fırat Cuylan Z; Koyuncu K; Salman MC; Özgül N; Meydanlı MM; Turan T; Ortaç F; Yüce K
    Balkan Med J; 2019 Jul; 36(4):229-234. PubMed ID: 30873825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
    Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
    Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
    Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
    Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
    Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
    Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
    McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
    Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
    Makker V; Kravetz SJ; Gallagher J; Orodel OP; Zhou Q; Iasonos A; DeLair D; Aghajanian C; Hensley ML
    Int J Gynecol Cancer; 2013 Nov; 23(9):1635-41. PubMed ID: 24172099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.
    Sarı ME; Meydanlı MM; Türkmen O; Cömert GK; Turan AT; Karalök A; Şahin H; Haberal A; Kocaman E; Akbayır Ö; Erdem B; Numanoğlu C; Güngördük K; Sancı M; Gökçü M; Özgül N; Salman MC; Boyraz G; Yüce K; Güngör T; Taşkın S; Altın D; Ortaç UF; Ayık HA; Şimşek T; Arvas M; Ayhan A
    J Gynecol Oncol; 2017 Jul; 28(4):e49. PubMed ID: 28541637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
    Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
    J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
    Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
    Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.
    Yamada SD; Burger RA; Brewster WR; Anton D; Kohler MF; Monk BJ
    Cancer; 2000 Jun; 88(12):2782-6. PubMed ID: 10870061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-stage carcinosarcoma of the uterus: the significance of lymph node count.
    Temkin SM; Hellmann M; Lee YC; Abulafia O
    Int J Gynecol Cancer; 2007; 17(1):215-9. PubMed ID: 17291256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaginal brachytherapy for early-stage carcinosarcoma of the uterus.
    Brown LC; Petersen IA; Haddock MG; Bakkum-Gamez JN; Lee LJ; Cimbak NC; Berkowitz RS; Viswanathan AN
    Brachytherapy; 2015; 14(4):433-9. PubMed ID: 25890795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.
    Cantrell LA; Havrilesky L; Moore DT; O'Malley D; Liotta M; Secord AA; Nagel CI; Cohn DE; Fader AN; Wallace AH; Rose P; Gehrig PA
    Gynecol Oncol; 2012 Oct; 127(1):22-6. PubMed ID: 22727985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.